BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine


5/7/2012 9:52:42 AM

GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study. The presentation was made at the 15th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Baltimore, MD. NDV-3 is a vaccine being developed for the prevention and treatment of diseases caused by Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 contains recombinant Als3, a surface adhesin/invasin from Candida albicans, which is the first vaccine antigen to demonstrate preclinical “cross-kingdom” protective efficacy against both fungal and bacterial pathogens. Results from the new study demonstrated that a single dose of NDV-3 with or without alum adjuvant was safe, well-tolerated and induced strong antibody and T-cell immune responses.

Read at BioSpace.com


   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->